Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency

Citation
Rd. Murray et al., Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency, CLIN ENDOCR, 52(5), 2000, pp. 537-542
Citations number
23
Categorie Soggetti
Endocrynology, Metabolism & Nutrition","Endocrinology, Nutrition & Metabolism
Journal title
CLINICAL ENDOCRINOLOGY
ISSN journal
03000664 → ACNP
Volume
52
Issue
5
Year of publication
2000
Pages
537 - 542
Database
ISI
SICI code
0300-0664(200005)52:5<537:PILITM>2.0.ZU;2-F
Abstract
OBJECTIVE Severe GH deficiency in adults is a definite clinical entity, the effects of which can be reversed by administration of subcutaneous recombi nant GH. The ideal dosing regimen and determinants of the maintenance dose have, however, yet to be elucidated. PATIENTS In an open study of GH replacement we treated 65 GH-deficient adul ts of mixed adult- and childhood-onset, of mean age 35.5 (range 17-72) year s, and comprising 38 females and 27 males, using an individualized low-dose titration regimen aimed at normalization of the serum IGF-I and induction of clinical improvement. RESULTS Before initiation of GH therapy, median IGF-I SD was significantly lower in female than male patients (-3.3 vs. -1.9, P=0.007) and in childhoo d-onset compared with adult-onset patients (-3.9 vs. - 2.0, P <0.001). Once maintenance dosage had been achieved, the median GH requirement was signif icantly greater in female than male patients (1.6 vs. 0.8 IU/day, P = 0.013 ) and childhood-onset compared with adult-onset patients (1.6 vs. 0.8 IU/da y, P = 0.019). The median maintenance GH dose for the cohort overall was 1. 2 (range 0.4-2.4) IU/day, By univariate analysis a significant negative cor relation was observed between the maintenance GH dose and baseline IGF-I SD (r= - 0.63, P< 0.001). No significant correlation was demonstrated between maintenance GH dose and either age or weight. Multiple linear regression a nalysis using age, gender, weight, time of onset of GH deficiency, peak GH to the insulin tolerance test (ITT) and baseline IGF-I SD as independent va riables demonstrated baseline IGF-I SD to account for 51% of the variation in GH dose required to normalize the IGF-I SD (P<0.001). Those patients wit h the lower IGF-I SD at initiation of GH therapy required the greater GH do se. None of the other variables studied significantly influenced the mainte nance dose. CONCLUSION We have demonstrated that the GH dose required in an individual is dependent on the serum IGF-I SD before commencement of replacement. In c ontrast, the severity of GH deficiency as judged by the peak GH response to an ITT was unrelated to the maintenance GH requirement, The effect of age, gender and age at onset of GH deficiency on the final GH dose are accounte d for by the lower pretreatment IGF-I SD in young, female and childhood-ons et patients relative to older, male and adult-onset patients, respectively.